Imutex value - Revised (more accurate)18 Jul 2020 19:14
I have had a deeper look at the valuation and conducted some basic factual analysis
Imutex has 2 main competitors for Universal Flu Vaccine Biondfax Bio & FluGen. Both these companies are 100% focused on the Flu vaccine. In order of progress
1. BiondFax - in phase 3 trials - Mkt cap ~$500M Nas listing. SP gone from $7 April - $43 now
2. Imutex - Completed phase 2, prep for phase 3 - Mkt cap TBC
3. FluGen - in Phase 2 - Mkt cap ~$412M Nas listing
If we float on Nas not only would we have our Universal flue vacine. Lets value between the Biond & FluGen - ~$450M. Then roll in the Mosquito vaccine Phase 1 comp - The vaccine, if it pans out, would protect against all of the pathogens the insects inject into humans – malaria, dengue, chikungunya, Zika, yellow fever, West Nile, Mayaro viruses and anything else that may emerge. Vaccine like this would be “the Holy Grail.” VALUE TBC lets say $50M
Then if we roll in PrepBio & Influenza Immune Modulator, value unknown - Value at $5M nominal value.
So based on that analysis we could have a Nas value somewhere North of $500M
Just highlights how undervalued we are and this is just for non core assets. Net to OO should be $200-300M